Small Biotech Companies Could Get Faster USPTO Review Of COVID-19 Patent Applications
Pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months; the prioritized examination is available solely for small entities and would save them $2,000.
You may also be interested in...
The U.S. Patent and Trademark Office is giving patent applicants the chance to get their applications processed within 12 months of submission for an additional fee of $4,000.
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.